Active, not recruitingPhase 2NCT05351164
Evaluation of Safety and Efficiency of Metreleptin Treatment for Patients With Multiple Symmetric Lipomatosis (MSL)
Studying Multiple symmetric lipomatosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Michigan
- Principal Investigator
- Elif Oral, MDUniversity of Michigan
- Intervention
- Metreleptin(drug)
- Enrollment
- 4 target
- Eligibility
- 60 years · All sexes
- Timeline
- 2023 – 2028
Study locations (1)
- University of Michigan, Ann Arbor, Michigan, United States
Collaborators
Amryt Pharma
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05351164 on ClinicalTrials.gov